Clinical trials: Hepatitis; Epidemic
Viral Hepatitis C
Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM
The study is aimed to provide high-risk, HIV-infection, men who have sex with men (MSM) with healthcare education regarding viral hepatitis C, through either serious game intervention or traditional online health education.
- Trial name
- NCT05751889
- Testing
- Serious Game, Traditional Health Education
- Where
- Taiwan
- Volunteers
- 1,320 people
- Sponsor
- National Taiwan University Hospital
Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies
Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency
Dysimmune and specially hepatic immuno-pathological processes are frequent in patients with PIDs (primary immune deficiencies), particularly but not exclusively in patients with humoral defects.
- Conditions
- Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, Combined Immunodeficiency (CID), Severe Combined Immunodeficiency (SCID)
- Trial name
- EVAH (NCT06659588)
- Testing
- Plasma, urine and stool collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Biliary Cirrhosis, Liver Inflammation
sCD163 in PBC Patients - Assessment of Treatment Response
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC.
- Conditions
- Primary Biliary Cirrhosis, Liver Inflammation, Ursodeoxycholic Acid
- Trial name
- NCT02931513
- Testing
- Blood samples, Fibroscan, Questionnaires
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University of Aarhus
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis E Virus Infection
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses…
- Trial name
- NCT06306196
- Testing
- Hecolin® Recombinant Hepatitis E Vaccine, Isotonic Sodium Chloride injection
- Where
- 3 sites in South Africa
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Liver Fibrosis
A Nomogram for Evaluating Significant Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection
Liver fibrosis is the key step for progression to cirrhosis and liver cancer in patients with chronic hepatitis B (CHB). It is crucial to identify significant liver fibrosis in the treatment of CHB patients.
- Trial name
- NCT05560503
- Volunteers
- 259 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Hepatitis C Genotype 1
The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)
The purpose of this study is to determine whether Boceprevir (BOC, SCH 503034, MK-3034) in combination with Peginterferon Alfa 2-b (PEG) plus Ribavirin (RBV) [PEG+RBV=PR] is effective in the treatment of chronic hepatitis C (CHC)…
- Trial name
- NCT01425203
- Testing
- Boceprevir, peginterferon alfa-2b, Ribavirin
- Volunteers
- 238 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-HAV vaccine in HIV-1 infected patients with CD4…
- Trial name
- HEPAVAC (NCT00190242)
- Testing
- group1, group2
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Chronic
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in…
- Trial name
- NCT01439373
- Testing
- GSK2336805, Pegylated interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
HIV Seropositivity, HCV Infection
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
This cross-sectional survey will be conducted prospectively in 2 communes in the Battambang Province, Roka and Prey Khpos commune.
- Trial name
- NCT04044586
- Where
- Cambodia
- Volunteers
- 1,098 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
The current study is a prospective, randomized, open, multi-center investigation. The aim of the study is to investigate whether the HBeAg seroconversion rate can be improved if applying combination therapy in HBeAg positive CHB…
- Trial name
- NCT03013556
- Testing
- Group A, TDF, Group B:TDF then TDF and Peginterferon alfa-2a, Group C:TDF and Peginterferon alfa-2a then TDF
- Where
- 8 sites in China
- Volunteers
- 180 people
- Sponsor
- Ruijin Hospital
Alcoholic Hepatitis
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
This multicenter, randomized, double blinded, placebo-controlled clinical trial is focused on novel treatments for severe alcoholic hepatitis (AH), a life-threatening stage of alcoholic liver injury that has a short-term…
- Trial name
- AlcHepNet (NCT04072822)
- Testing
- Anakinra and Zinc, Prednisone
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Indiana University
Hepatocellular Carcinoma
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health. In Egypt, HCC constitutes a significant public health problem.
- Trial name
- NCT04220151
- Testing
- DNA methylation
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
- Trial name
- NCT05853718
- Testing
- Tenofovir Alafenamide Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Hangzhou
Chronic Hepatitis b
The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.
In Taiwan, non-cirrhosis CHB patients with mildly elevated ALT are not candidates for antiviral treatment under Taiwan NIH reimbursement criteria.
- Trial name
- NCT04674423
- Testing
- Tenofovir Alafenamide
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Cheng-Kung University Hospital
Non-Alcoholic Fatty Liver Disease
NAFLD Study: US vs Liver Biopsy
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery…
- Trial name
- NAFLD (NCT04101162)
- Testing
- shear waves elastography; liver biopsy
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Human Papillomavirus Infection
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
Rationale: In march 2009 the Dutch Health Council advised to introduce general infant hepatitis B (HBV) vaccination in the Dutch national immunization program (NIP) {Gezondheidsraad 2009 #16914}.
- Trial name
- TANGO (NCT01082861)
- Testing
- Cervarix, Engerix-B
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute for Public Health and the Environment (RIVM)
Non-Hodgkin's Lymphoma
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients
This is a single-arm study. Key eligibility criteria include (1) newly diagnosed, diffuse large B-cell or follicular cell non-Hodgkin's lymphoma; (2) negative test for hepatitis B surface antigen (HBsAg) and positive for antibody…
- Trial name
- NCT00931229
- Testing
- entecavir
- Where
- Taiwan
- Volunteers
- 202 people
- Sponsor
- National Health Research Institutes, Taiwan
Hepatitis C
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
The purpose of this study is to determine the decline of virus in the blood and liver in patients treated with telaprevir, pegylated interferon and ribavirin.
- Trial name
- NCT00892697
- Testing
- Telaprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
The Difficult-to-treat Chronic Hepatitis B
A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy
Antiviral resistance remains an important issue for long-term NA therapy. For lamivudine (LAM), the rtM204V/I and rtL180M mutations occur in more than 70% after 5 years of therapy.
- Trial name
- NCT02019966
- Where
- South Korea
- Volunteers
- 1,020 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.